Report overview
Anti-HER2 Therapy is a class of medicines used to treat all stages of HER2-positive breast cancer and certain HER2-low breast cancers.In HER2-positive breast cancer, the HER2 (human epidermal growth factor receptor 2) gene doesn?t work correctly and makes too many copies of itself. These extra HER2 genes make too many proteins known as HER2 receptors.Anti-HER2 medicines attach to the HER2 receptor proteins on the surface of breast cancer cells.Anti-HER2 medicines work by blocking the HER2 receptors from receiving the growth signals in HER2-positive breast cancer. By blocking the growth signals, anti-HER2 medicines can slow or stop the growth of HER2-positive and HER2-low breast cancer. Anti-HER2 medicines only work on HER2-positive and HER2-low breast cancer. They do not work on HER2-negative breast cancer.
This report aims to provide a comprehensive presentation of the global market for Anti-HER2 Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-HER2 Therapy. This report contains market size and forecasts of Anti-HER2 Therapy in global, including the following market information:
Global Anti-HER2 Therapy Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Anti-HER2 Therapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Anti-HER2 Monoclonal Antibodies Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Anti-HER2 Therapy include GlaxoSmithKline, Bayer, Abbott, AbbVie, Pfizer, Sanofi, Merck, Glenmark Pharmaceuticals and Roche, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Anti-HER2 Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Anti-HER2 Therapy Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Anti-HER2 Therapy Market Segment Percentages, by Type, 2022 (%)
Anti-HER2 Monoclonal Antibodies
Antibody-Drug Conjugate
Kinase Inhibitors
Global Anti-HER2 Therapy Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Anti-HER2 Therapy Market Segment Percentages, by Application, 2022 (%)
Online Pharmacy
Retail Pharmacy
Medical Clinics
Global Anti-HER2 Therapy Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Anti-HER2 Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Anti-HER2 Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Anti-HER2 Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline
Bayer
Abbott
AbbVie
Pfizer
Sanofi
Merck
Glenmark Pharmaceuticals
Roche
Novartis
Astra Zeneca
Daiichi Sankyo
Celltrion
Teva
Biocon
Viatris
Outline of Major Chapters:
Chapter 1: Introduces the definition of Anti-HER2 Therapy, market overview.
Chapter 2: Global Anti-HER2 Therapy market size in revenue.
Chapter 3: Detailed analysis of Anti-HER2 Therapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-HER2 Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
